DDrare: Database of Drug Development for Rare Diseases

Searched query = "Bronchiolitis obliterans", "Obliterating bronchiolitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 5-Methyl-1-Phenyl-2-1-(H)-Pyridone; AZITHROMYCIN; AZITHROMYCIN DIHYDRATE; AZITHROMYCINE; AZITHROMYCINE 250 mg; AZM; Adipate; Aerolised Liposomal Ciclosporin A; Aerolised Liposomal Ciclosporin A 10mg; Aerolised Liposomal Ciclosporin A 5mg; Azithromycin; Azithromycin (Zitromax°); Azithromycin + N-acetylcystein + inhaled corticosteroid; Azithromycine; Aztreonam; Aztreonam Lysine for Inhalation (AZLI); Basiliximab; Bortezomib; Budesonide; Budesonide/formoterol; CICLOSPORIN A; COLECALCIFEROL; Certican; Certican 0,5; Certican 0,5 mg Tabletten; Certican 0,75mg; Certican 0,75mg Tabletten; Chloride; Ciclosporin; Ciclosporin (Ciclosporinium); Ciclosporina; Ciclosporina / Ciclosporin; Ciclosporina A Liposomica Aerolised Liposomal Ciclosporin A; Ciclosporina/ Ciclosporin; Ciclosporine; Ciclosporine A; Ciclosporine, Ciclosporina; Ciclosporine, ciclosporina; Clarithromycin; Cloruro de Sodio; Cloruro de sodio; Colecalciferol; CsA; Cyclosporine; Cyclosporine A dry powder inhalation (Drug); Cyclosporine Inhalation Solution; Cyclosporine Inhalation Solution (CIS); D-Cure; D-cure; ERL080; Enteric coated mycophenolate sodium; Erythromycin; Esbriet; Etanercept; Everolimus; FAM Therapy; Fluticasone; Fluticasone propionate; Formoterol; Formoterol/Budesonide; Glucocorticoid; Helium; Helium-3; Hp 129Xenon; Hyperpolarized Helium-3 MRI; INTERFERON GAMMA-1B; Imukin; Inhalation; Interferon Gamma; Interferon gamma 1b; Interferon gamma-1b; Itacitinib; Itacitinib Adipate; L-CsA; Lactose; Liposomal Cyclosporine A; Liposomal Cyclosporine A 10 mg; Liposomal Cyclosporine A 5 mg; Liposomal aerosol cyclosporine; Lysine; MONTELUKAST SODIUM; MPH966; MSCs; Mesenchymal stem cell 0.5; Mesenchymal stem cell 1.0; Montelukast; Montelukast Teva; Montelukast sodium; Montelukast teva; Mycophenolate; Myfortic; Nintedanib; OFEV; OTHER SOURCES; Other: EIT; Other: Inhaled Hyperpolarized Xenon-129; Other: Salbutamol nebulisation and with CPAP; Other: standard immune suppression, oral; PIRFENIDONE; Pirfenidone; Pirfenidone 267 MG [Esbriet]; Prednisone; Procedure: Pulmonary function testing; Procedure: Status Post Lung Transplant; RAD001; Ruxolitinib; Salbutamol; Seretide; Singulair; Singulair (Montelukast Sodium); Sodium Chloride; Sodium Chloride Solution; Sodium Chloride Solvent; Sodium Chloride solvent; Sodium chloride; Solucion de Cloruro de Sodio; Solucion de cloruro de sodio Sodium Chloride Solution; Solvente Cloruro de Sodio Sodium Chloride Solvent; Solvente de Cloruro de Sodio; Symbicort; Tacrolimus; Vitamin D; Xenon; Zithromax; Zitromax

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01307462 (ClinicalTrials.gov)	June 2011	1/3/2011	Targeted Therapy of Bronchiolitis Obliterans Syndrome	Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant	Bronchiolitis Obliterans	Drug: fluticasone propionate;Drug: montelukast sodium;Drug: azithromycin	Stephanie Lee	National Cancer Institute (NCI)	Completed	6 Years	99 Years	All	36	Phase 2	United States
2	EUCTR2010-021983-14-BE (EUCTR)	23/09/2010	02/09/2010	A randomized placebo-controlled double blind study to treat BOS.	A randomized placebo-controlled double blind study to treat BOS.	-Mortality at 1 and 2 year post diagnosis of BOS-Infection rate during BOS-Evolution of pulmonary function after diagnosis of BOS MedDRA version: 12.1;Level: LLT;Classification code 10029888;Term: Obliterative bronchiolitis MedDRA version: 12.1;Classification code 10049202;Term: Bronchiolitis obliterans MedDRA version: 12.1;Classification code 10068805;Term: Follicular bronchiolitis MedDRA version: 12.1;Classification code 10019319;Term: Heart-lung transplant rejection MedDRA version: 12.1;Classification code 10025127;Term: Lung transplant MedDRA version: 12.1;Classification code 10051604;Term: Lung transplant rejection MedDRA version: 12.1;Classification code 10056409;Term: Heart and lung transplant MedDRA version: 12.1;Classification code 10016547;Term: FEV MedDRA version: 12.1;Classification code 10016549;Term: FEV 1 abnormal MedDRA version: 12.1;Classification code 10016550;Term: FEV 1 decreased MedDRA version: 12.1;Classification code 10016553;Term: FEV 1 low	Trade Name: Montelukast Teva Product Name: montelukast teva Product Code: NA INN or Proposed INN: MONTELUKAST SODIUM Other descriptive name: Singulair	UZ Gasthuisberg	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30		Belgium
3	NCT00656058 (ClinicalTrials.gov)	June 17, 2008	9/4/2008	Montelukast to Treat Bronchiolitis Obliterans	Multi-Institutional Prospective Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic or Autologous Stem Cell Transplantation in Children and Adults	Bronchiolitis Obliterans;Chronic Graft Versus Host Disease;Leukotriene;Montelukast;Stem Cell Transplant	Drug: Singulair (Montelukast Sodium)	National Cancer Institute (NCI)	NULL	Completed	6 Years	80 Years	All	25	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01307462
(ClinicalTrials.gov)

June 2011

1/3/2011

Targeted Therapy of Bronchiolitis Obliterans Syndrome

Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant

Bronchiolitis Obliterans

Drug: fluticasone propionate;Drug: montelukast sodium;Drug: azithromycin

Stephanie Lee

National Cancer Institute (NCI)

Completed

6 Years

99 Years

All

Phase 2

United States

EUCTR2010-021983-14-BE
(EUCTR)

23/09/2010

02/09/2010

A randomized placebo-controlled double blind study to treat BOS.

-Mortality at 1 and 2 year post diagnosis of BOS-Infection rate during BOS-Evolution of pulmonary function after diagnosis of BOS
MedDRA version: 12.1;Level: LLT;Classification code 10029888;Term: Obliterative bronchiolitis
MedDRA version: 12.1;Classification code 10049202;Term: Bronchiolitis obliterans
MedDRA version: 12.1;Classification code 10068805;Term: Follicular bronchiolitis
MedDRA version: 12.1;Classification code 10019319;Term: Heart-lung transplant rejection
MedDRA version: 12.1;Classification code 10025127;Term: Lung transplant
MedDRA version: 12.1;Classification code 10051604;Term: Lung transplant rejection
MedDRA version: 12.1;Classification code 10056409;Term: Heart and lung transplant
MedDRA version: 12.1;Classification code 10016547;Term: FEV
MedDRA version: 12.1;Classification code 10016549;Term: FEV 1 abnormal
MedDRA version: 12.1;Classification code 10016550;Term: FEV 1 decreased
MedDRA version: 12.1;Classification code 10016553;Term: FEV 1 low

Trade Name: Montelukast Teva
Product Name: montelukast teva
Product Code: NA
INN or Proposed INN: MONTELUKAST SODIUM
Other descriptive name: Singulair

UZ Gasthuisberg

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Belgium

NCT00656058
(ClinicalTrials.gov)

June 17, 2008

9/4/2008

Montelukast to Treat Bronchiolitis Obliterans

Multi-Institutional Prospective Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic or Autologous Stem Cell Transplantation in Children and Adults

Bronchiolitis Obliterans;Chronic Graft Versus Host Disease;Leukotriene;Montelukast;Stem Cell Transplant

Drug: Singulair (Montelukast Sodium)